Pharmacoeconomic review report : Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) (Gilead Sciences Canada, Inc.)

Pharmacoeconomic review report Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) (Gilead Sciences Canada, Inc.)

Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX; Vosevi) is a single tablet that combines sofosbuvir with velpatasvir and voxilaprevir. It is recommended as a 12-week, single-tablet regimen for the treatment of chronic hepatitis C virus (HCV) infection for patients without cirrhosis or with compens...

Descripción completa

Detalles Bibliográficos
Autor principal: Canadian Agency for Drugs and Technologies in Health (author)
Autor Corporativo: Canadian Agency for Drugs and Technologies in Health, author, issuing body (author)
Formato: Libro electrónico
Idioma:Inglés
Publicado: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health 2018.
Colección:Common drug review clinical review report.
Materias:
Medicine > Research.
Cost effectiveness.
Drug interactions.
Ver en Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820267806719
Tabla de Contenidos:
  • Abbreviations
  • Executive Summary
  • Background
  • Summary of Identified Limitations and Key Results
  • Conclusions
  • Information on the Pharmacoeconomic Submission
  • Summary of the Manufacturer's Pharmacoeconomic Submission
  • Manufacturer's Base Case
  • Summary of Manufacturer's Sensitivity Analyses
  • Limitations of Manufacturer's Submission
  • CADTH Common Drug Review Reanalyses
  • Issues for Consideration
  • Patient Input
  • Conclusions
  • Appendix 1. Cost Comparison
  • Appendix 2. Additional Information
  • Appendix 3. Reviewer Worksheets
  • References.

Ejemplares similares